Annual Accounts Receivable
$30.55 M
-$9.77 M-24.23%
31 December 2023
Summary:
Rigel Pharmaceuticals annual accounts receivable is currently $30.55 million, with the most recent change of -$9.77 million (-24.23%) on 31 December 2023. During the last 3 years, it has risen by +$14.58 million (+91.26%). RIGL annual accounts receivable is now -24.23% below its all-time high of $40.32 million, reached on 31 December 2022.RIGL Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$30.57 M
+$1.67 M+5.78%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly accounts receivable is currently $30.57 million, with the most recent change of +$1.67 million (+5.78%) on 30 September 2024. Over the past year, it has increased by +$7.03 million (+29.85%). RIGL quarterly accounts receivable is now -78.50% below its all-time high of $142.19 million, reached on 31 March 2021.RIGL Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.2% | +29.9% |
| 3 y3 years | +91.3% | +104.0% |
| 5 y5 years | +649.3% | +164.7% |
RIGL Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -24.2% | +97.5% | -24.2% | +104.0% |
| 5 y | 5 years | -24.2% | +649.3% | -78.5% | +216.5% |
| alltime | all time | -24.2% | -78.5% |
Rigel Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $30.57 M(+5.8%) |
| June 2024 | - | $28.90 M(+5.1%) |
| Mar 2024 | - | $27.51 M(-9.9%) |
| Dec 2023 | $30.55 M(-24.2%) | $30.55 M(+29.7%) |
| Sept 2023 | - | $23.55 M(+13.1%) |
| June 2023 | - | $20.82 M(-29.1%) |
| Mar 2023 | - | $29.37 M(-27.2%) |
| Dec 2022 | $40.32 M(+160.6%) | $40.32 M(+159.7%) |
| Sept 2022 | - | $15.53 M(-9.7%) |
| June 2022 | - | $17.20 M(+12.8%) |
| Mar 2022 | - | $15.24 M(-1.5%) |
| Dec 2021 | $15.47 M(-3.1%) | $15.47 M(+3.2%) |
| Sept 2021 | - | $14.99 M(-13.7%) |
| June 2021 | - | $17.37 M(-87.8%) |
| Mar 2021 | - | $142.19 M(+790.2%) |
| Dec 2020 | $15.97 M(+58.0%) | $15.97 M(+9.2%) |
| Sept 2020 | - | $14.63 M(+24.8%) |
| June 2020 | - | $11.73 M(+21.4%) |
| Mar 2020 | - | $9.66 M(-4.5%) |
| Dec 2019 | $10.11 M(+148.0%) | $10.11 M(-12.5%) |
| Sept 2019 | - | $11.55 M(+66.6%) |
| June 2019 | - | $6.93 M(+23.5%) |
| Mar 2019 | - | $5.61 M(+37.7%) |
| Dec 2018 | $4.08 M(>+9900.0%) | $4.08 M(+24.6%) |
| Sept 2018 | - | $3.27 M(+102.0%) |
| June 2018 | - | $1.62 M(>+9900.0%) |
| Dec 2017 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2016 | - | $0.00(-100.0%) |
| June 2016 | - | $95.00 K(-51.3%) |
| Mar 2016 | - | $195.00 K(-3.9%) |
| Dec 2015 | $203.00 K | $203.00 K(+24.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $163.00 K(-53.4%) |
| June 2015 | - | $350.00 K(+230.2%) |
| Mar 2015 | - | $106.00 K(-98.2%) |
| Dec 2014 | $5.75 M(0.0%) | $5.75 M(>+9900.0%) |
| Sept 2014 | - | $0.00(0.0%) |
| June 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(-100.0%) |
| Dec 2013 | $5.75 M(>+9900.0%) | $5.75 M(>+9900.0%) |
| Dec 2012 | $0.00(-100.0%) | $0.00(-100.0%) |
| Mar 2010 | - | $100.00 M(>+9900.0%) |
| June 2007 | - | $485.00 K(-56.1%) |
| Mar 2007 | - | $1.10 M(0.0%) |
| Dec 2006 | $1.10 M(+5.1%) | $1.10 M(+5.1%) |
| Sept 2006 | - | $1.05 M(0.0%) |
| June 2006 | - | $1.05 M(-35.6%) |
| Mar 2006 | - | $1.63 M(+55.2%) |
| Dec 2005 | $1.05 M(-9.0%) | $1.05 M(0.0%) |
| Sept 2005 | - | $1.05 M(-11.1%) |
| June 2005 | - | $1.18 M(-26.6%) |
| Mar 2005 | - | $1.61 M(+39.5%) |
| Dec 2003 | $1.15 M(-23.2%) | $1.15 M(-32.9%) |
| Sept 2003 | - | $1.72 M(+139.7%) |
| June 2003 | - | $717.00 K(-51.3%) |
| Mar 2003 | - | $1.47 M(-2.1%) |
| Dec 2002 | $1.50 M(+30.4%) | $1.50 M(+1304.7%) |
| Sept 2002 | - | $107.00 K(-93.9%) |
| June 2002 | - | $1.76 M(-30.3%) |
| Mar 2002 | - | $2.53 M(+119.3%) |
| Dec 2001 | $1.15 M | $1.15 M(-68.6%) |
| Sept 2001 | - | $3.68 M(+616.6%) |
| June 2001 | - | $513.00 K(-66.3%) |
| Mar 2001 | - | $1.52 M |
FAQ
- What is Rigel Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual accounts receivable year-on-year change?
- What is Rigel Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Rigel Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of RIGL is $30.55 M
What is the all time high annual accounts receivable for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual accounts receivable is $40.32 M
What is Rigel Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, RIGL annual accounts receivable has changed by -$9.77 M (-24.23%)
What is Rigel Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of RIGL is $30.57 M
What is the all time high quarterly accounts receivable for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly accounts receivable is $142.19 M
What is Rigel Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, RIGL quarterly accounts receivable has changed by +$7.03 M (+29.85%)